Coagulation Factor IX for Hemophilia B Therapy

被引：27
|
作者：
Orlova, N. A. [1 ,2 ]
Kovnir, S. V. [1 ,2 ]
Vorobiev, I. I. [1 ,2 ]
Gabibov, A. G. [1 ]
机构：
[1] Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[2] Minist Healthcare & Social Dev Russian Federat, Hematol Res Ctr, Moscow 125167, Russia
来源：
ACTA NATURAE | 2012年 / 4卷 / 02期
关键词：
coagulation factor IX; hemophilia B; heterologous protein expression systems; CLOTTING FACTOR-IX; RECOMBINANT FACTOR-IX; SUSTAINED PHENOTYPIC CORRECTION; PREVIOUSLY TREATED PATIENTS; MEDIATED GENE-TRANSFER; LONG-TERM CORRECTION; HUMAN PROTEIN-C; FACTOR-X; PHARMACOKINETIC PROPERTIES; STRUCTURAL-ANALYSIS;
D O I：
10.32607/20758251-2012-4-2-62-73
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy. Reviewed herein are the current state in the manufacturing of FIX, improved variants of the recombinant protein for therapy, transgenic organisms for obtaining FIX, and the advances in the gene therapy of hemophilia B.
引用
收藏
页码：62 / 73
页数：12
相关论文
共 50 条
  • [31] Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX
    Ramaswamy, Suvasini
    Tonnu, Nina
    Menon, Tushar
    Lewis, Benjamin M.
    Green, Kevin T.
    Wampler, Derek
    Monahan, Paul E.
    Verma, Inder M.
    CELL REPORTS, 2018, 23 (05): : 1565 - 1580
  • [32] Optimized human factor IX expression cassettes for hepaticdirected gene therapy of hemophilia B
    Ru Zhang
    Qiang Wang
    Lin Zhang
    Saijuan Chen
    Frontiers of Medicine, 2015, 9 (01) : 90 - 99
  • [33] Hemophilia B therapy with 15nm filtered factor IX-LFB
    Derlon, A
    PRESSE MEDICALE, 1998, 27 (15): : 740 - 741
  • [34] Extravascular administration of factor IX: Potential for replacement therapy of canine and human hemophilia B
    Liles, D
    Landen, CN
    Monroe, DM
    Lindley, CM
    Read, MS
    Roberts, HR
    Brinkhous, KM
    THROMBOSIS AND HAEMOSTASIS, 1997, 77 (05) : 944 - 948
  • [35] Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
    Nathwani, A. C.
    Reiss, U. M.
    Tuddenham, E. G. D.
    Rosales, C.
    Chowdary, P.
    McIntosh, J.
    Della Peruta, M.
    Lheriteau, E.
    Patel, N.
    Raj, D.
    Riddell, A.
    Pie, J.
    Rangarajan, S.
    Bevan, D.
    Recht, M.
    Shen, Y. -M.
    Halka, K. G.
    Basner-Tschakarjan, E.
    Mingozzi, F.
    High, K. A.
    Allay, J.
    Kay, M. A.
    Ng, C. Y. C.
    Zhou, J.
    Cancio, M.
    Morton, C. L.
    Gray, J. T.
    Srivastava, D.
    Nienhuis, A. W.
    Davidoff, A. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21): : 1994 - 2004
  • [36] Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B
    Nayak, Sushrusha
    Sarkar, Debalina
    Perrin, George Q.
    Moghimi, Babak
    Hoffman, Brad E.
    Zhou, Shangzhen
    Byrne, Barry J.
    Herzog, Roland W.
    FRONTIERS IN MICROBIOLOGY, 2011, 2
  • [37] A factor IX-deficient mouse model for hemophilia B gene therapy.
    Wang, L
    Zoppe, M
    Hackeng, TM
    Griffin, JH
    Lee, KF
    Verma, IM
    BLOOD, 1997, 90 (10) : 2530 - 2530
  • [38] Treatment of hemophilia B: focus on recombinant factor IX
    Franchini, Massimo
    Frattini, Francesco
    Crestani, Silvia
    Sissa, Cinzia
    Bonfanti, Carlo
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 33 - 38
  • [39] Recombinant human factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B
    Brinkhous, KM
    Sigman, JL
    Read, MS
    Stewart, PF
    McCarthy, KP
    Timony, GA
    Leppanen, SD
    Rup, BJ
    Keith, JC
    Garzone, PD
    Schaub, RG
    BLOOD, 1996, 88 (07) : 2603 - 2610
  • [40] FACTOR-IX RELATED ANTIGEN IN HEMOPHILIA B
    YANG, HC
    LEVINE, PH
    THROMBOSIS AND HAEMOSTASIS, 1977, 38 (01) : 348 - 348
12345